{"name":"TransMolecular","slug":"transmolecular","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"131-I-TM-601","genericName":"131-I-TM-601","slug":"131-i-tm-601","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"131I-TM-601","genericName":"131I-TM-601","slug":"131i-tm-601","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"131-I-TM-601","genericName":"131-I-TM-601","slug":"131-i-tm-601","phase":"phase_2","mechanism":"131-I-TM-601 is a targeted alpha-particle therapy that selectively targets and destroys cancer cells.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"131I-TM-601","genericName":"131I-TM-601","slug":"131i-tm-601","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1meGUyVHBuZktwRFBoaDdOUlF6cGFPblZLNEMtY1hPaHRhQ0pWZkhWTjV5X2lEa01vOGY0dmdxY05DVnVpM1RkVmh6NkowMTA1Tms0TkY2cWE?oc=5","date":"2024-06-19","type":"pipeline","source":"Pharma Voice","summary":"From Scorpion to Cancer - Pharma Voice","headline":"From Scorpion to Cancer","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}